Tislelizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tislelizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target PD-1
Clinical data
Synonyms BGB-A317
ATC code
  • none
Identifiers
ChemSpider
  • none

Tislelizumab[1][2] (BGB-A317) is a humanized monoclonal antibody directed against PD-1.[3] It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.[3]

It is designed to bind less to Fc gamma receptors.[4]

It is being developed by BeiGene and Celgene Corp.[5]

Clinical trials[edit]

Phase I trials began in the US and Australia in June 2015 and were expected to complete in mid-2017.[6] Some early results were announced in July 2016.[7][3]

A pivotal phase 2 clinical trial for urothelial cancer started in China in 2017.[4]

It is in a phase 3 trial for NSCLC.[8]

A multicenter phase 3 trial for advanced hepatocellular carcinoma started in Jan 2018.[5]

Pharmacokinetics[edit]

Early phase I clinical trial results give an elimination half-life of 11 to 17 days.[3]

References[edit]